BAK1 and acute lymphoblastic leukemia: According to Flores et al. [67], the Bax/Bak-independent impact of tBid on MOM integrity and cell viability may open up new therapeutic perspectives in the fight against venetoclax-resistant acute lymphocytic leukemia (ALL) cells.